What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force - 21/11/24
, E. Siemers 2, D. Michelson 33, S. Salloway 4, C. Sampaio 5, M.C. Carrillo 6, R. Sperling 7, R. Doody 8, P. Scheltens 9, R. Bateman 10, M. Weiner 11, B. Vellas 12EU/US/CTAD Task Force members
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Abstract |
Although the results were disappointing from two recent clinical trials of amyloid-targeting drugs in mild-to-moderate AD, the trials provided information that will be important for future studies, according to the EU-US CTAD Task Force, which met in November 2017 to discuss the EXPEDITION3 and EPOCH trials. These trials tested two of the predominant drug development strategies for AD: amyloid immunotherapy and BACE inhibition in populations largely composed of mild AD dementia patients. The results of these trials support the emerging consensus that effective amyloid-targeted treatment will require intervention in early, even pre-symptomatic stages of the disease. Further, the Task Force suggested that a refinement of the amyloid hypothesis may be needed and that other hypotheses should be more fully explored. In addition, they called for improved biomarkers and other outcome assessments to detect the earliest changes in the development of AD.
Il testo completo di questo articolo è disponibile in PDF.Key words : Alzheimer’s disease, therapeutic trials
Mappa
| E.U./U.S. CTAD TASK FORCE: Susan Abushakra (Framingham); Joan Amatniek (Princeton); Sandrine Andrieu (Toulouse); Joanne Bell (Wilmington); Gene Bowman (Lausanne); Sasha Bozeat (Utrecht); Samantha Budd Haeberlein (Cambridge); Marc Cantillon (Livingston); Marither Chuidian (Aliso Viejo); Doina Cosma-Roman (Aliso Viejo); Jeffrey Cummings (Las Vegas); Anne De Jong-Laird (Wexham); Sanjay Dubé (Aliso Viejo); Michael Egan (North Wales); Laura Eggermont (Utrecht); Phyllis Ferrell (Indianapolis); Erin Foff (Princeton); Terence Fullerton (New York); Sylvie Gouttefangeas (Suresnes); Michael Grundman (San Diego); Suzanne Hendrix (Salt Lake City); David Hewitt (Wilmington); Carole Ho (South San Francisco); Patrick Kesslak (Princeton); Valérie Legrand (Nanterre), Stefan Lind (Valby); Constantine (Kostas) Lyketsos (Baltimore); Richard Margolin (New York); Thomas Megerian (Aliso Viejo); Annette Merdes (Munich); David Michelson (Cambridge); Mark Mintun (Philadelphia); Jacobo Mintzer (Charleston); Tina Olsson (Cambridge); Ronald Petersen (Rochester); Jana Podhorna (Ingelheim am Rhein); Stephane Pollentier (Ingelheim am Rhein); Anton Porsteinsson (Rochester); Rema Raman (San Diego); Murray Raskind (Seattle); Gary Romano (Beerse); Paul Rosenberg (Baltimore); Juha Rouru (Turku); Ivana Rubino (Cambridge); Ricardo Sainz-Fuertes (Wexham); Mary Sano (New York); Rachel Schindler (New York); Mark Schmidt (Beerse); Jeroen Schmitt (Lausanne); Lon Schneider (Los Angeles); Peter Schüler (Langen); Märta Segerdahl Storck (Valby); John Sims (Indianapolis); LeAnne Skordos (Cambridge); Maria Soto (Toulouse); Bjorn Sperling (Cambridge); Joyce Suhy (Newark); Jacques Touchon (Montpellier); Serge Van der Geyten (Beerse); Philipp Von Rosenstiel (Cambridge); Michael Weiner (San Francisco); (Glen Wunderlich (Ridgefield); Haichen Yang (North Wales); Jerry Yang (New York) |
Vol 5 - N° 3
P. 171-174 - Luglio 2018 Ritorno al numero
Articolo precedente
- Fatty acids and Alzheimer’s Disease: Evidence on Cognition and Cortical β-amyloid from Secondary Analyses of the Multidomain Alzheimer Preventive Trial
- Claudie Hooper, B. Vellas, MAPT/DSA study group
- Effects of a Six-Month Multi-Ingredient Nutrition Supplement Intervention of Omega-3 Polyunsaturated Fatty Acids, vitamin D, Resveratrol, and Whey Protein on Cognitive Function in Older Adults: A Randomised, Double-Blind, Controlled Trial
- Catherine Moran, A. Scotto di Palumbo, J. Bramham, A. Moran, B. Rooney, G. De Vito, B. Egan
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.